HC Wainwright Boosts Earnings Estimates for COMPASS Pathways

COMPASS Pathways plc (NASDAQ:CMPS) – Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for COMPASS Pathways in a report issued on Thursday, February 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.34) for the quarter, up from their previous estimate of ($0.51). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($1.38) EPS and FY2027 earnings at ($0.92) EPS.

Other equities analysts have also issued research reports about the company. Royal Bank of Canada restated an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Maxim Group cut their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, COMPASS Pathways presently has an average rating of “Buy” and a consensus target price of $30.60.

COMPASS Pathways Stock Down 2.9 %

NASDAQ:CMPS opened at $4.44 on Monday. COMPASS Pathways has a twelve month low of $3.16 and a twelve month high of $12.75. The company has a market cap of $303.58 million, a price-to-earnings ratio of -2.02 and a beta of 2.28. The stock has a fifty day simple moving average of $4.09 and a 200-day simple moving average of $5.40. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15.

Hedge Funds Weigh In On COMPASS Pathways

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPS. China Universal Asset Management Co. Ltd. purchased a new position in COMPASS Pathways in the fourth quarter valued at about $41,000. Flagship Harbor Advisors LLC purchased a new position in COMPASS Pathways in the fourth quarter valued at about $43,000. Wealthfront Advisers LLC purchased a new position in COMPASS Pathways in the fourth quarter valued at about $43,000. Conservest Capital Advisors Inc. grew its stake in COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. purchased a new position in COMPASS Pathways in the fourth quarter valued at about $54,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.